Lancer Drugs And Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 29-12-2024
- Paid Up Capital ₹ 0.10 M
as on 29-12-2024
- Company Age 18 Year, 11 Months
- Last Filing with ROC 31 Mar 2016
- Open Charges ₹ 4.35 M
as on 29-12-2024
- Revenue 44.36%
(FY 2016)
- Profit -166.40%
(FY 2016)
- Ebitda -641.29%
(FY 2016)
- Net Worth -27.60%
(FY 2016)
- Total Assets -26.33%
(FY 2016)
About Lancer Drugs And Pharmaceuticals India
The Corporate was formerly known as Lancer Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2016. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.35 M.
Mathew Joseph and Githin Mathew serve as directors at the Company.
- CIN/LLPIN
U52311KL2006PTC019061
- Company No.
019061
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Jan 2006
- Date of AGM
29 Sep 2016
- Date of Balance Sheet
31 Mar 2016
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Lancer Drugs And Pharmaceuticals India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mathew Joseph  | Managing Director | 12-Jan-2006 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Githin Mathew | Director | 12-Jan-2006 | Current |
Financial Performance of Lancer Drugs And Pharmaceuticals India.
Lancer Drugs And Pharmaceuticals India Private Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 44.36% increase. The company also saw a substantial fall in profitability, with a 166.4% decrease in profit. The company's net worth observed a substantial decline by a decrease of 27.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lancer Drugs And Pharmaceuticals India?
In 2016, Lancer Drugs And Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Federal Bank Limited Creation Date: 29 Jun 2013 | ₹4.35 M | Open |
How Many Employees Work at Lancer Drugs And Pharmaceuticals India?
Unlock and access historical data on people associated with Lancer Drugs And Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lancer Drugs And Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lancer Drugs And Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
